Plus Therapeutics presented an update on the ongoing ReSPECT-GBM Phase 1/2 clinical trial, evaluating Rhenium (186Re) Obisbemeda for the treatment of recurrent glioblastoma at the 2024 Congress of Neurological Surgeons (CNS) Annual Meeting yesterday.
Key Highlights/PR: https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-reports-respect-gbm-clinical-trial-update-2024
Presentation: https://plustherapeutics.com/wp-content/uploads/2024/09/CNS-2024_ReSPECT-GBM_Phase-2-Update.pdf
#glioblastoma #braincancer #braintumor #gbm #clinicaltrial #cancer #oncology #cancerresearch #neurosurgery #CNS2024 $PSTV
Recent Comments